This site is not optimized for Internet Explorer 8 (or older).

Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.

Empagliflozin in Heart Failure with a Preserved Ejection Fraction

Thursday, October 21, 2021

Submitted by


Source Name: The New England Journal of Medicine


EMPEROR-Preserved Trial Investigators

A large randomised double-blinded trial reporting a considerable benefit ( 0.79 HR with very small p and supporting confidence intervals) of the Boehringer SGLPT-2 inhibitor regardless of presence of formal diagnosis of diabetes. If corroborated by further research and thence included on guidelines  , the findings may alter the standard of pharmacological care of our surgical patients, namely coronopaths and vasculopaths .  

Add comment

Log in or register to post comments